Christine Cumarasamy, MD
Urology · Hartford, CTNPI 1003158106
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,922 of the $5,810 with a category attached, or 67.5%. 32 manufacturers reported payments, led by Intuitive Surgical at 30.5% of the total. Reporting peaked in 2023 at $1,618 and has fallen 52.5% since, to $769 in 2025.
Across 105 payments — averaging $55.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- Boston Scientific$1K
- Axonics, Inc.$577
- Johnson & Johnson$441
- Covidien LP$289
- Procept Biorobotics Corporation$252
- plus $1K from 26 others
Across 5 payments — averaging $1960.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Covidien LP$10K
What the payments were for
- Travel & lodging$1,85832%
- Food & beverage$3,92267%
- Education$301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $1,774 |
| Boston Scientific | 18 | $1,124 |
| Axonics, Inc. | 10 | $577 |
| Johnson & Johnson(2 entities) | 6 | $441 |
| Covidien LP | 3 | $289 |
| Procept Biorobotics Corporation | 2 | $252 |
| Coloplast | 5 | $216 |
| Medtronic(2 entities) | 3 | $137 |
| Conmed Corporation | 1 | $130 |
| Bayer | 5 | $86 |
| Tolmar, Inc. | 5 | $80 |
| Laborie Medical Technologies Corp. | 2 | $64 |
| Olympus America Inc. | 3 | $57 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $56 |
| Ferring Pharmaceuticals Inc. | 3 | $54 |
| Urogen Pharma, Inc. | 3 | $52 |
| Myovant Sciences Inc. | 3 | $45 |
| Astellas Pharma US Inc | 3 | $41 |
| Teleflex LLC | 1 | $33 |
| Pfizer | 2 | $32 |
| Merck | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $31 |
| Urovant Sciences Inc | 2 | $28 |
| Tolmar Pharmaceuticals, Inc. | 2 | $27 |
| Myriad Genetic Laboratories, Inc. | 2 | $26 |
| Mimedx Group, Inc. | 1 | $25 |
| Kerecis Limited | 1 | $25 |
| Calyxo, Inc. | 1 | $24 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $11 |
| Hollister Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,713
- STRATAFIX$282
- AquaBeam Robotic System$252
- GENERAL ERECTILE DYSFUNCTION$250
- Axonics$208
- Bulkamid$208
- Echelon Flex$165
- AIRSEAL$130
- GENERAL KIDNEY STONE DISEASE$120
- Erleada$117
- VISTASEAL$117
- INTERSTIM$102
How this compares
$5,810 in reported general payments places this provider in the 70th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 280 | $188,679 |
| GemtesaVibegron | 101 | $105,998 |
| Solifenacin Succinate | 364 | $17,224 |
| Estradiol | 191 | $13,688 |
| Tamsulosin Hcl | 448 | $7,887 |
| Mirabegron ErMirabegron | 11 | $5,801 |
| Potassium Citrate ErPotassium Citrate | 29 | $3,017 |
| Oxybutynin Chloride | 122 | $2,713 |
| Finasteride | 201 | $2,645 |
| Methenamine Hippurate | 43 | $2,535 |
| Trospium Chloride | 21 | $1,199 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 80 | $1,003 |
| Oxybutynin Chloride ErOxybutynin Chloride | 45 | $951 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 28 | $801 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $41 | $188,679280 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $105,998101 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 156 urology providers in Connecticut.
Other urology in Hartford
- Steven ShichmanHartford$28K
- Joseph WagnerHartford$21K
- Eric KatzHartford$14K
- Jared BieniekHartford$9K
- Shanta ShepherdHartford$8K
- Guy TronoHartford$6K
- Abram DamatoHartford$6K
- Peter BoscoHartford$3K
- Aaron TurnquistHartford$3K
- Daniel KellnerNew Haven$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.